Impact of Chronic Obstructive Pulmonary Disease on Incidence, Microbiology and Outcome of Ventilator-Associated Lower Respiratory Tract Infections.
chronic obstructive pulmonary disease
intensive care
lower respiratory tract infections
mechanical ventilation
pneumonia
tracheobronchitis
ventilator-associated
Journal
Microorganisms
ISSN: 2076-2607
Titre abrégé: Microorganisms
Pays: Switzerland
ID NLM: 101625893
Informations de publication
Date de publication:
23 Jan 2020
23 Jan 2020
Historique:
received:
03
01
2020
accepted:
18
01
2020
entrez:
26
1
2020
pubmed:
26
1
2020
medline:
26
1
2020
Statut:
epublish
Résumé
To determine the impact of chronic obstructive pulmonary disease (COPD) on incidence, microbiology, and outcomes of ventilator-associated lower respiratory tract infections (VA-LRTI). Planned ancillary analysis of TAVeM study, including 2960 consecutive adult patients who received invasive mechanical ventilation (MV) > 48 h. COPD patients (n = 494) were compared to non-COPD patients (n = 2466). The diagnosis of ventilator-associated tracheobronchitis (VAT) and ventilator-associated pneumonia (VAP) was based on clinical, radiological and quantitative microbiological criteria. No significant difference was found in VAP (12% versus 13%, p = 0.931), or VAT incidence (13% versus 10%, p = 0.093) between COPD and non-COPD patients. Among patients with VA-LRTI, Escherichia coli and Stenotrophomonas maltophilia were significantly more frequent in COPD patients as compared with non-COPD patients. However, COPD had no significant impact on multidrug-resistant bacteria incidence. Appropriate antibiotic treatment was not significantly associated with progression from VAT to VAP among COPD patients who developed VAT, unlike non-COPD patients. Among COPD patients, patients who developed VAT or VAP had significantly longer MV duration (17 days (9-30) or 15 (8-27) versus 7 (4-12), p < 0.001) and intensive care unit (ICU) length of stay (24 (17-39) or 21 (14-40) versus 12 (8-19), p < 0.001) than patients without VA-LRTI. ICU mortality was also higher in COPD patients who developed VAP (44%), but not VAT(38%), as compared to no VA-LRTI (26%, p = 0.006). These worse outcomes associated with VA-LRTI were similar among non-COPD patients. COPD had no significant impact on incidence or outcomes of patients who developed VAP or VAT.
Identifiants
pubmed: 31979375
pii: microorganisms8020165
doi: 10.3390/microorganisms8020165
pmc: PMC7074722
pii:
doi:
Types de publication
Journal Article
Langues
eng
Déclaration de conflit d'intérêts
S.N.: MSD, Pfizer, Biomérieux, Gilead (lecture and advisory board). A.R.: MaatPharma (advisory board). Appendix A. Other authors declare that they have no competing interests.
Références
Lancet Infect Dis. 2013 Aug;13(8):665-71
pubmed: 23622939
Intensive Care Med. 2015 Jan;41(1):34-48
pubmed: 25427866
Am J Respir Crit Care Med. 2013 Jul 15;188(2):220-30
pubmed: 23631814
Crit Care Med. 2006 Dec;34(12):2959-66
pubmed: 17012911
Curr Opin Crit Care. 2014 Oct;20(5):525-31
pubmed: 24999921
Ann Transl Med. 2018 Nov;6(21):418
pubmed: 30581826
Ann Intensive Care. 2013 Apr 12;3(1):10
pubmed: 23587445
Eur J Clin Microbiol Infect Dis. 2015 Dec;34(12):2403-11
pubmed: 26407622
Intensive Care Med. 2013 Sep;39(9):1547-55
pubmed: 23812339
Lancet Respir Med. 2015 Nov;3(11):859-68
pubmed: 26472037
Antimicrob Agents Chemother. 2010 Nov;54(11):4851-63
pubmed: 20733044
Am J Med. 2013 Jun;126(6):542-9
pubmed: 23561632
Infect Control Hosp Epidemiol. 2013 Aug;34(8):800-8
pubmed: 23838220
Crit Care. 2006;10(5):R143
pubmed: 17026755
Am J Respir Crit Care Med. 2013 Feb 15;187(4):347-65
pubmed: 22878278
Am J Respir Crit Care Med. 2011 Nov 15;184(10):1133-9
pubmed: 21852541
Clin Microbiol Infect. 2012 Mar;18(3):268-81
pubmed: 21793988
Am Rev Respir Dis. 1990 Sep;142(3):523-8
pubmed: 2202245
Crit Care. 2014 Feb 12;18(1):R32
pubmed: 24521533
Chest. 2018 Mar;153(3):601-610
pubmed: 28802696
J Crit Care. 2006 Mar;21(1):56-65
pubmed: 16616625
Eur Respir J. 2002 Dec;20(6):1483-9
pubmed: 12503708
Chest. 2011 Mar;139(3):513-518
pubmed: 20724738
Eur Respir J. 2013 Apr;41(4):792-9
pubmed: 23018915
Chest. 2011 Jun;139(6):1354-1360
pubmed: 21393392
Intensive Care Med. 2016 Jul;42(7):1190-2
pubmed: 27080532
Respir Med. 2011 Jul;105(7):1022-9
pubmed: 21435855
Chest. 2005 Sep;128(3):1650-6
pubmed: 16162771